Head and neck squamous cell carcinoma (HNSCC) includes epithelial cancers of the oral and nasal cavity, larynx, and pharynx and accounts for ~350,000 deaths/year worldwide. Smokingrelated HNSCC is associated with few targetable mutations but is defined by frequent copy number alteration, the most common of which is gain at 3q. Critical 3q target genes have not been conclusively determined for HNSCC. Here we present data indicating that MAP3K13 These results were validated in vivo by evidence that LZK silencing was sufficient to reduce tumor growth in a xenograft model of HNSCC. Our results establish LZK as critical for maintaining expression of mutant stabilized p53.
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INTRODUCTION
HNSCC is driven by frequent copy number alteration, the most common of which is gain of 3q, the long arm of chromosome 3 (1) . Drivers identified on the 3q amplicon include PIK3CA (2,3), TP63 (4) (5) (6) , and SOX2 (7-9); however, targeting amplified PIK3CA has displayed limited success (10, 11) , and small molecule inhibitors do not exist for SOX2 or p63, thus additional drivers must be identified to improve outcomes for HNSCC patients. We investigated the kinase LZK (encoded by MAP3K13, a resident gene on the 3q amplicon) as a novel target because it was previously reported to regulate the JNK (12, 13) and NFB (14) pathways, which can be protumorigenic. There are few studies describing the function of LZK, but a previous study demonstrated that LZK and its close family member DLK play a role in synaptic growth.
Specifically, the DLK/LZK Drosophila homolog, wallenda, is required for synaptic overgrowth (15) , and overexpression of LZK can promote axon growth in neurons (16) . In addition, DLK/LZK inhibitors have been developed and show activity in a Parkinson's disease mouse model (17) .
Mutation or deletion of TP53 (encoding p53) is a frequent and early event in the development of HNSCC (1) . Wild-type p53 is a critical tumor suppressor; however, many TP53 mutations produce a full-length protein, which is highly expressed in cancer cell lines (18) . Several hotspot mutations have been identified and demonstrated to have oncogenic capabilities (reviewed in 19, 20) , including the ability to transform p53-null cells and promote tumor growth in mice (21) . Gain-of-function (GOF) p53 mutants are associated with antiapoptotic (22, 23) , pro-proliferative (24) (25) (26) and pro-invasive phenotypes (25, 27) , and can promote resistance to chemotherapy (24, 28) . GOF p53 mutants have been shown to upregulate cyclins A and B1 (26) , hTERT (29) , MDR1 (21) , NF B2 (30) and MYC (31) , and downregulate p21, PTEN, BAX (22) and caspase-3 (28) . GOF p53 has also been shown to interact with and inhibit AMPK (32) , and modulate chromatin regulatory factors, including MLL1, MLL2, and MOZ (33) . GOF mutant p53 is stabilized by tumor cell-specific factors (34) , the mechanisms of which are not fully understood. Currently, no therapeutics have been specifically developed to suppress the expression of stabilized mutant p53; however, HSP90 inhibitors were previously shown to reduce expression of mutant p53 (23) . Here we describe LZK as essential to maintain proliferation of HNSCC cells with 3q gain, via promoting stability of GOF mutant p53.
MATERIALS AND METHODS

Plasmids and transfections
LZK cDNA was prepared from RNA extracted from 293T cells, attB flanking regions were added by PCR, and the BP clonase reaction used to insert LZK into pDONR221. From here the Invitrogen Gateway system was used for cloning into destination vectors. FLAG-tagged (pReceiver-M12, GeneCopoeia) destination vector was converted into Gateway destination vector for use in transient overexpression assays. The pLenti6.3/TO/V5-DEST vector was used to generate stable overexpression. Mutations were introduced using a Site-Directed Mutagenesis Kit (Stratagene). Kinase dead (KD) construct used for LZK was a K195M mutant. For the shRNA-resistant LZK construct, mutations were as follows: g978t, t981c, a984g, t987a, c990g, t993c, a996g.
293T, CAL33 and BEAS2B cells were transiently transfected using Attractene (Qiagen) according to manufacturer's protocol. BICR56 cells were transfected using Lipofectamine LTX & Plus reagent (Invitrogen) according to manufacturer's protocol. A pcDNA3.1(+) vector (Invitrogen) was used as an empty vector control where required. DharmaFECT1 (Thermo Scientific) was used for siRNA transfections. siRNA used for LZK was obtained from Origene and used at 10 nM. Sequences were as follows: GGAACACGAUGAAUCAGAGACGGCG (siLZKA), GGCGAAUAAUUUAUACAUGGAAUTG (siLZKB) and AGAACAGAAUGAGACGGAUAUCAAG (siLZKC). siRNA to p53 was ordered from Santa
Cruz (si-p53#1; sc-29435) and Cell Signaling Technology (si-p53#2; 6231) and used at 100 nM. Non-targeting control siRNA was ordered from Dharmacon (D-001810-01-20), and used at the same concentration as siRNA to the appropriate target. Staurosporine was purchased from Cell Signaling Technology. removed from freeze for a short time after receipt for collection of DNA and RNA so were not authenticated. 3q status of all HNSCC and immortalized control cell lines were verified inhouse. All cell lines were used in experiments for fewer than 20 passages (10 weeks) after thawing, before a fresh vial was taken from freeze. Cell lines in use were confirmed to be mycoplasma-negative every 1-2 months.
Generation of doxycycline-inducible knockdown cell lines
CAL33, BICR56, OKF6/TERT2, BEAS2B, DETROIT562, and BICR6 inducible knockdown cells were generated by Sirion Biotech. MSK921 and BICR22 were generated in-house using lentiviral particles provided by Sirion (generated by transfection of 293TN cells with expression vectors and lentiviral packaging plasmids). Transduction was at MOI 5 with 8 g/ml polybrene. After 24 h, medium was replaced with fresh medium containing puromycin (Invitrogen) to select for cells that had been effectively transduced. shRNA sequences were:
CGGAATGAACCTGTCTCTGAA (sh1), GATGTAGATTCTTCAGCCATT (sh2) and AAGAGCCGATATCGAAGCAAA (sh3). The lentiviral expression plasmid was pCLVi(3G)-MCS-Puro, which expresses a doxycycline-responsive transactivator and the shRNA from the same vector. Expression of the transactivator is constitutive, while expression of shRNA is dependent on a doxycycline-inducible promoter. Binding of doxycycline to the transactivator allows it to bind the doxycycline-inducible promoter and promote expression of the shRNA. Doxycycline (Sigma) was used at 1 g/ml to induce knockdown of LZK.
Generation of tetracycline-inducible expression cell lines
The ViraPower HiPerform T-Rex Gateway Expression System (Invitrogen) was used to generate cells with tetracycline-inducible expression of LZK. Briefly, LZK (cloned into pLenti6.3/TO/V5-DEST vector) and pLenti3.3/TR (for tetracycline repressor expression) were transfected into 293FT cells using Lipofectamine2000 to generate lentiviral stock. Parental OKF6/TERT2 and BEAS2B cells were transduced with lentiviral stocks in a stepwise fashion and cell lines generated by antibiotic selection (Blasticidin (Invitrogen) and Geneticin (Gibco)). Tetracycline (Invitrogen) was used at 1 g/ml to induce expression of LZK.
RNA preparation
48 h after treatment (transient transfection, tetracycline-induced overexpression, or doxycycline-induced knockdown), cells were lysed using RLT buffer (Qiagen) with 1% v/v 2-mercaptoethanol (BioRad). Removal of genomic DNA and preparation of RNA was conducted using an RNeasy kit (Qiagen) according to manufacturer's protocol. The quantity of RNA was determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies).
RT-PCR
RT-PCR was performed using SuperScript III One-Step RT-PCR kit (Invitrogen 
Protein lysate preparation and immunoblots
After appropriate treatment time, cells were lysed on ice with Triton X-100 lysis buffer (Cell Signaling Technology) supplemented with protease inhibitor tablet (Roche). Antibodies used:
Phosphoarrays
Two phosphoarrays were used: a phospho-kinase array and a MAPK array (both from R&D Systems). Samples were lysed 48 h after induction by tetracycline or doxycycline as appropriate. Protocols were as manufacturer's instructions.
MTT cell viability assays
Cells were seeded into 96-well plates in triplicate. For transient knockdown, cells were transfected at the same time as seeding and analyzed 72 h later. For inducible knockdown, doxycycline was added into the medium the following day and analyzed 72 h later. MTT Kit (Sigma) was used to assess viability, using protocol as manufacturer's instructions.
MTS cell viability assays
For MTS assays, Cell Titer 96 Aqueous One Solution cell proliferation assay (Promega) was used, following the manufacturer's protocol. Briefly, cells were reverse transfected with the corresponding p53 siRNA or negative control. 24 h later, cells were collected and seeded into 96-well plates in triplicate for MTS assay, and 6-well plates for protein extraction.
Doxycycline was added where appropriate and cells incubated for 72 h. MTS was added, incubated for 4 h and absorbance measured at 490 nm.
Cell proliferation assays
Cells were seeded into 96-well plates in triplicate, and doxycycline added into the medium the following day. Cells were treated for 48 h before incubation with BrdU label for a further 24 h prior to analysis by Calbiochem kit according to manufacturer's instructions.
Relative cell density assays
Crystal violet assays were used to assess relative cell growth and survival after knockdown.
For transient knockdown, cells were transfected at the same time as seeding and analyzed 72 h later. For inducible knockdown, cells were seeded into 6-well plates in triplicate, treated with doxycycline the following day, and plates analyzed after 72 h treatment. Cells were then washed with PBS and fixed in ice-cold methanol, before staining with 0.5% crystal violet in 25% methanol. For quantification, crystal violet stain was dissolved in 10% acetic acid, incubated for 20 min with shaking, and read at 595 nm.
Colony formation assays
Cells were seeded into 6-well plates in triplicate at 300/well (BEAS2B and OKF6/TERT2 controls) or 1000/well (HNSCC cell lines), and treated with doxycycline the following day.
Medium was refreshed every 48 h for 14 days. Cells were stained with crystal violet as described above.
Matrigel assay
The '3D on-top assay' (35) was used to assess growth in matrigel. Matrigel used was Growth
Factor Reduced, Phenol Red-Free Basement Membrane Matrix from mouse EHS tumor (Corning). Matrigel was thawed at 4 C overnight. Plates and tips were pre-chilled prior to experiment, and experiment was conducted on ice, except where specified. 12-well plates were coated with 200 l matrigel and incubated at 37 C for 30 min. Cells were plated at 80,000/well in 0.5 ml medium and left to settle for 30 min at 37 C. 0.5 ml 5% matrigel in medium was added gently to each well. The following day, cells were treated with 1 g/ml doxycycline where required. After 72 h treatment, plates were observed with an Axiovert 40 CFL Inverted Microscope, and photographs taken with the aid of AxioVision software. The 'Color Threshold' tool in ImageJ was used to assess average colony size. Three images per condition were used for measurement, and average colony size calculated for each condition.
Cell cycle analysis
Cells were seeded into 6-well plates and treated with doxycycline the following day. After 
Statistical analysis
Error bars shown on graphs represent ±SEM. Two-tailed Welch's t-test was used to assess significance of differences between groups for assays. Analysis of variance (ANOVA) analysis was conducted to assess the significance of differences in mRNA expression between groups based on GISTIC copy numbers.
Copy number analysis
DNA from cell lines was prepared using a Qiagen Blood & Tissue kit, according to manufacturer's instructions. Copy number analysis was conducted by paired-end whole genome sequencing (2 x 100 bp reads) on an Illumina HiSeq 2000. 30 million pairs per samples were generated, which gave ~two-fold coverage of the genome. The most common ploidy was defined as 'normal' for the purposes of assessing copy number gain and loss.
RESULTS
Amplification and expression of LZK/MAP3K13 in HNSCC
Examination of data from The Cancer Genome Atlas (TCGA) revealed that high level amplification of MAP3K13 was present in 20% of HNSCC tumors (Fig. 1A) , while an additional 56% had copy number gain (38) . Furthermore, MAP3K13 was within the top 100 most frequently amplified genes on chromosome 3 (Fig. 1B) . Further analysis of TCGA tumor samples indicated that higher MAP3K13 copy number was associated with significantly increased mRNA expression (Fig. 1C) . In addition, data from the Cancer Cell Line Encyclopedia ( Fig 1D) . Copy number analysis confirmed the presence of the 3q amplicon in almost all HNSCC cell lines tested (Fig. 1D) . MSK921 was the only HNSCC cell line tested that had no alteration at 3q (Fig. 1D) . BICR22 was notable for the fact that its region of copy number gain did not encompass MAP3K13 (Fig. 1D) . Therefore, BICR22 and MSK921 were chosen as control HNSCC cell lines. qRT-PCR showed that a majority of the cell lines with copy number gain of MAP3K13 had increased mRNA expression (Fig. 1E) , confirming data observed for TCGA human primary tumor samples. Finally, western blot analysis indicated increased LZK protein levels in cells with 3q gain compared with BEAS2B cells (Supplementary Fig. S1B ).
LZK knockdown by siRNA reduces viability of HNSCC cells with copy number gain
To determine whether LZK is important for maintaining tumorigenic phenotypes, siRNAmediated knockdown was conducted. Three individual siRNAs effectively depleted LZK protein levels in CAL33 and BICR56 HNSCC cells, and in OKF6/TERT2 and BEAS2B control lines (Fig. 2A) . All three LZK siRNAs caused a highly significant reduction in viability in CAL33 and BICR56 cells, but had no effect on BEAS2B or OKF6/TERT2 cells (Fig. 2B ).
In addition, crystal violet staining, which was used to assess relative cell growth and survival,
showed that knockdown of LZK decreased the cell density of CAL33 and BICR56 cells (Fig.   2C-D) . No effect was observed in OKF6/TERT2 controls, although a minor reduction in cell density was seen for BEAS2B cells with siLZKB and siLZKC ( Fig. 2C-D) .
LZK knockdown by doxycycline-inducible shRNA reduces viability, colony formation, and growth in vivo of HNSCC cells with 3q gain
To validate these data, HNSCC cells with doxycycline-inducible expression of shRNA targeting MAP3K13 were generated (Fig. 3A-B) . Induced knockdown of LZK led to a 40-50% reduction in viability of CAL33 and BICR56 cells, but had no significant effect on viability of MSK921 or BICR22 control cell lines that lack MAP3K13 copy number gain (Fig. 3C) .
Consistent with these results, there was a ~50% decrease in crystal violet staining in CAL33
and BICR56 cells after doxycycline-induced LZK knockdown, but no effect on MSK921 or BICR22 cells ( Supplementary Fig. S2A-B) . To confirm these data in a 3D setting that more closely mimics the tumor microenvironment, cells were grown in matrigel; colony sizes of CAL33 and BICR56 cells were reduced after LZK knockdown, whereas no significant effect was seen for control cell lines (Fig. 3D-E) . Clonogenicity was then assessed; a near complete ablation of colony forming ability was observed for CAL33 and BICR56 cells after depletion of LZK (Fig. 3F, Supplementary Fig. S2C ). MSK921 cells showed a smaller reduction in colony formation after doxycycline treatment; this effect occurred at least in part due to the toxicity of doxycycline, which also affected the parental cell line (Fig. 3F, Supplementary Fig.   S2C ). Doxycycline has been reported to have toxic effects on some cell lines (40, 41) , and this toxicity is likely more pronounced when cells are seeded at a low density (42) , which could explain why these effects were not seen in short-term assays. LZK depletion did not suppress growth of BICR22 cells (Fig. 3F, Supplementary Fig. S2C ).
Critically, re-expression of the sh1-resistant LZK construct into CAL33-sh1 and BICR56-sh1 cells fully or partially, respectively, rescued the effect of LZK knockdown on cell density, confirming that these effects were specific to LZK depletion (Fig. 4A) . LZK knockdown was then conducted in additional control and HNSCC cell lines (Fig. 4B) . shRNAmediated depletion of LZK resulted in a significant reduction in colony formation in two additional HNSCC lines with 3q gain (BICR6 and DETROIT562), but not in BEAS2B or OKF6/TERT2 immortalized control cell lines (Fig. 4C-D) . To determine the importance of LZK in vivo, we established a murine xenograft model using the CAL33-sh1 cell line. There was a significant reduction in tumor growth of 39% ± 16% upon doxycycline treatment ( Fig.   4E ; note doxycycline diet had no significant effect on parental CAL33 xenografts ( Supplementary Fig. S3A) ). These results highlight the importance of LZK as a regulator of viability in HNSCC.
LZK knockdown by doxycycline-inducible shRNA reduces proliferation and cell cycle progression of HNSCC cells with copy number gain
Phenotypic assays were then carried out to investigate potential mechanisms of reduced viability. BrdU assays showed that depletion of LZK significantly reduced proliferation of CAL33 and BICR56 cells, while no effects were observed in control cells (Fig. 5A) . The decrease seen was to a similar extent as that observed in viability and density assays, suggesting that this proliferative decrease may be the main mechanism underpinning these effects. To confirm these results, propidium iodide staining was used to assess the effect of LZK knockdown on progression through the cell cycle. An increase in the percentage of cells in G1 phase was observed for CAL33 and BICR56 inducible knockdown cells depleted of LZK, but not for MSK921 control cells (Fig. 5B, Supplementary Table S1 ). This correlated with an increase in G1/S ratio, a measure of cell cycle arrest, of approximately three-fold for CAL33 and two-fold for BICR56 (Fig. 5C ). These data verify that LZK regulates HNSCC viability through regulation of the cell cycle. Additionally, PARP cleavage, a marker of apoptosis, was not observed after LZK knockdown ( Supplementary Fig. S3B ), suggesting that LZK does not regulate cell death in HNSCC.
LZK knockdown leads to a reduction in levels of stabilized mutant p53
To identify pathways involved in the pro-proliferative effect of LZK, we monitored the activation status of pathways described to be activated by LZK: JNK (12,13), p38 (13) , and NF B (14) (Supplementary Fig. S4A ). In overexpression assays we observed activation of JNK, but not p38 or NF B ( Supplementary Fig. S4B-F) . However, in BICR56 and CAL33 cells, there was no decrease in phospho-JNK after transient or inducible knockdown (Supplementary Fig. S4G-H ; note that minor reductions were observed for MSK921 cells, but this was also seen in parental MSK921 cells, suggesting that doxycycline may be responsible for the reduction in pJNK in this cell line). This suggested that these pathways were not responsible for the reduced proliferation observed after LZK depletion.
To elucidate other pathways regulated by LZK, a phospho-kinase array was conducted using CAL33 inducible knockdown cells. The most obvious differences seen were for three p53 phosphorylation sites (S15, S46 and S392) (Fig. 6A) . The phospho-p53 results were validated by western blot for the S392 phospho-site; however, it was found that total p53 levels were reduced after LZK knockdown (Fig. 6B) , accounting for the observed decrease in phospho-p53 at the three phospho-sites. Effects on p53 were then investigated in BICR56 cells; p53 levels were also markedly reduced in this cell line after depletion of LZK (Fig. 6C) .
No reductions in total p53 were observed in MSK921 cells ( Fig. 6C ; note doxycycline treatment alone did not alter p53 levels in parental cells ( Supplementary Fig. S5A) ).
Notably, CAL33 has a known GOF mutation in p53 (R175H), so a decrease in total p53
would be expected to lead to reduced proliferation. In contrast, the MSK921 control cell line harbors wild-type p53. BICR56 has a mutation in p53 that leads to the exclusion of seven amino acids (Y126-K132) at the beginning of exon 5. To date, this mutant has not been characterized. Transient knockdown using siRNA was conducted to investigate the function of p53 in these cell lines ( Supplementary Fig. S5B-C) . Knockdown of p53 in CAL33 cells led to a 40-60% reduction in viability ( Fig. 6D; Supplementary Fig. S5C ), indicating that LZK primarily promotes viability by maintaining expression of GOF mutant p53 in these cells. In BICR56 cells, knockdown of p53 led to a smaller but significant decrease in viability of 30-40% ( Fig. 6D; Supplementary Fig. S5C ), suggesting that these cells also require expression of stabilized mutant p53.
To determine if E3 ubiquitin ligases MDM2 or MDM4 were contributing to loss of expression of GOF mutant p53, expression of these two proteins was monitored in cells depleted of LZK. Endogenous MDM4 was not detected in any of the HNSCC cell lines and endogenous MDM2 was only detected in the CAL33 cells ( Supplementary Fig. S6A ). There was no increase in MDM2 protein levels in CAL33 cells depleted of LZK (Supplementary Fig.   S6B ). Overall, these data indicate that regulation of these E3 ubiquitin ligases is not an underlying mechanism contributing to loss of p53 expression in HNSCC cells depleted of LZK.
To further understand the mechanism by which the LZK-GOF p53 pathway is promoting increased proliferation we assessed activation and expression of targets downstream of GOF mutant p53 (22, 27) . Depletion of LZK resulted in increased levels of p21 and phospho-AMPK in CAL33 and BICR56 cells (Fig. 6E) , consistent with previous reports that GOF mutant p53 suppresses these downstream targets. These results highlight a novel signaling pathway where LZK is required to maintain expression of GOF mutant p53, which regulates activation of AMPK and expression of p21. Finally, re-expression of shRNA-resistant LZK in CAL33 and BICR56 cells restored levels of mutant p53, demonstrating that this effect was specifically due to depletion of LZK (Fig. 6F) .
DISCUSSION
HNSCC accounts for approximately 600,000 cases and 350,000 deaths per year worldwide (43, 44) . A majority of patients present with stage III or IV disease, and, after treatment, 50%
will have disease progression within 2 years (45,46). 5-year survival rates for patients who present with advanced disease are under 50% (47) . At present, the current treatment regimens for later stages involve chemotherapy and/or radiotherapy, which carry significant toxicities (46, 48) . Chemotherapy or radiotherapy can be enhanced by combination with cetuximab, which targets EGFR, in advanced stages of the disease (49, 50) . EGFR is overexpressed in ~90% of HNSCC patients; however, only a small subset (13%) of patients respond to cetuximab monotherapy (51). Additionally, the inclusion of cetuximab to a regimen of chemoradiotherapy was not found to have any additional benefit, regardless of EGFR Rather than targetable mutations, the most common genetic alterations in HNSCC are somatic copy number alterations, the most frequent of which is copy number gain at 3q (1).
Multiple genes on the 3q amplicon can promote tumorigenic phenotypes, including PIK3CA (2,3), TP63 (4-6), and SOX2 (7) (8) (9) , and detailed studies must be undertaken to define the contribution of the various genes on this amplicon to tumor initiation and maintenance. Knockdown of LZK led to a reduction in protein levels of GOF mutant p53 in cells with 3q gain; this was also rescued by re-expression of shRNA-resistant LZK. GOF mutant p53 has been well documented to promote proliferation (24) (25) (26) . In contrast to the wild-type protein, GOF mutant p53 is found at constitutively high levels in cancer cells (18) . However, the mutant proteins are not inherently more stable than the wild-type, as demonstrated by expression in normal tissue compared with tumor tissue in transgenic mice (34) ; this implies that GOF mutants are stabilized by tumor cell-specific factors. Our study highlights amplified LZK as one potential contributor to the maintenance of mutant p53 stability in HNSCC cells.
When LZK was depleted, we also observed increases in levels of phospho-AMPK and p21, both of which are negatively regulated by GOF p53 (22, 27) . Based on these observations, we propose a model whereby amplified LZK promotes stability of GOF mutant p53, which in turn promotes proliferation of HNSCC cells via regulation of its downstream targets, including p21
and AMPK (Fig. 6G) . The mechanism by which LZK stabilizes mutant p53 will be the focus of future studies.
In summary, our data indicate that LZK promotes proliferation in HNSCC with 3q copy number gain, via maintaining expression of stabilized mutant p53. Enzymes that regulate stability of GOF mutant p53 are attractive targets given the incidence of stabilized mutant p53 across all cancers. It was recently reported that over 11 million cancer patients live with stabilized mutant p53 (23); thus, LZK may represent a druggable genetic dependency for a subset of these patients where LZK is amplified. 
ACKNOWLEDGMENTS
